Men's Health Facebook ad: “The Coroner Doesn't Write 'Diabetes' On The Death…”

About this ad

Meta Ad Library ID

1578798693791556

Platforms

Facebook, Instagram, Audience Network, Messenger and Threads

Relaunches

0

How we count

Ad text

When a diabetic dies of cardiac arrest at 62, the coroner writes "acute myocardial infarction" on the death certificate. He doesn't write "his A1C was 6.4 the day he died and his metformin had been working perfectly on the numbers his GP was watching for 11 years." He doesn't write "his fasting insulin had never been measured and his HOMA-IR had quietly climbed into the severe insulin resistance range while everyone watched his A1C." He doesn't write "the inflammation his C-reactive protein would have shown — if anyone had ordered the test — had been silently building damage in his coronary arteries for the entire decade he was 'well-controlled.'" There is a reason for that, and it has nothing to do with paperwork. It has to do with what diabetes actually is. And once you understand what it actually is, you understand why metformin, glipizide, and the standard insulin cascade have never once reversed the underlying disease that drives Type 2 diabetes — and why a fibrinolytic enzyme that has been consumed in Japanese fermented food for thousands of years may matter more to you, personally, than any prescription your endocrinologist has ever written. I want to tell you what Type 2 diabetes actually is in middle-aged adults. Not the textbook definition. The real one. Diabetes is a disease of insulin signaling failure disguised as a disease of high blood sugar. Your pancreas is not "failing with age." It is exhausted from compensating for cellular insulin resistance that has been progressing in your muscle, liver, and fat cells for ten or fifteen years before your A1C first crossed 5.7. The high blood sugar is the symptom you noticed. The fasting glucose climbing from 89 to 102 to 116. The A1C creeping from 5.4 to 5.9 to 6.3. The post-meal sleepiness. The mid-section weight that won't move no matter what you do. These are what brought you to your doctor. These are what got you the metformin prescription. These are what your annual physical is tracking. But the actual damage — the damage that ends in diabetic retinopathy, in peripheral neuropathy, in chronic kidney disease, in erectile dysfunction, in the cardiac event that kills 70% of Type 2 diabetics — is happening underneath the blood sugar number you measure. In the cellular insulin receptors that have stopped responding. In the chronic systemic inflammation those failing receptors produce. In the microvasculature of every organ in your body — including the coronary arteries that will eventually decide how you die. Your body is one of the most insulin-dependent systems in nature. Every cell in your liver, your muscles, and your adipose tissue carries insulin receptors that, when functioning properly, allow glucose to move from your bloodstream into your cells. When those receptors become resistant — from chronic systemic inflammation, from oxidative stress, from the same vascular damage that is happening in your retinal vessels and your peripheral nerves and your penile arteries — your pancreas compensates by pumping out more insulin. Your fasting insulin climbs. The chronic hyperinsulinemia then drives more inflammation, more weight gain around the middle, and progressive damage in the smallest vessels in your body. The high blood sugar is the symptom. The insulin resistance and the inflammation are the disease. And here is the part that connects insulin resistance to the cardiovascular event that kills most Type 2 diabetics. The chronic inflammation driving insulin resistance is the same inflammation that causes fibrin — a sticky protein mesh — to deposit along the inside of your arterial walls. Fibrin is your body's emergency repair material. Every time inflammation damages a vessel wall, fibrin is laid down to patch the damage. In a young, healthy body, fibrinolytic enzymes dissolve the fibrin after the repair is done. The mesh clears. The artery stays open. In a body running chronic systemic inflammation from insulin resistance, the fibrin never stops being laid down — because the inflammation never stops. And past 40, the enzyme systems that dissolve fibrin slow dramatically. The fibrin accumulates. Layer after layer, year after year, narrowing every artery from the inside. The blood itself thickens — viscosity increases as fibrin fragments circulate in the bloodstream. The combination — narrower passages and thicker blood — means less blood reaches the tissues that need it. Your muscle cells get less oxygen and less glucose delivery. Your pancreatic beta cells get less perfusion. Your peripheral nerves starve. Your kidneys starve. Your retinal vessels starve. The insulin resistance worsens because the very tissues that need to respond to insulin are being choked of the blood supply they need to function. It is a loop. Insulin resistance drives inflammation. Inflammation drives fibrin deposition. Fibrin narrows the microvasculature. Narrowed microvasculature worsens insulin resistance. The loop accelerates every year it runs unchecked. It's all the same disease. Diabetic retinopathy. Peripheral neuropathy. Chronic kidney disease. Erectile dysfunction. Cognitive decline. Statin-induced worsening of glucose tolerance. The myocardial infarction that kills 70% of Type 2 diabetics. They are not seven separate complications. They are seven faces of one problem — chronic insulin signaling failure, the inflammation it produces, the fibrin that inflammation deposits inside every artery in your body, and a standard treatment protocol that addresses none of it. The American Diabetes Association acknowledges insulin resistance on its own patient pages. The 2024 ADA Standards of Care explicitly identifies insulin resistance as the central pathophysiologic feature of Type 2 diabetes. Your endocrinologist knows this. Your endocrinologist has known this since residency. Now here is the part that should make you angry. There is not a single intervention in the standard Type 2 diabetes protocol that targets the cellular insulin receptor, the underlying inflammation driving its dysfunction, or the fibrin accumulation that is choking off the microvasculature feeding every insulin-sensitive tissue in your body. Metformin reduces hepatic glucose output. It does not restore insulin receptor sensitivity in your muscle cells or your fat cells. It lowers the A1C number by reducing how much glucose your liver releases — not by repairing the receptors that are failing to respond to insulin. It does not dissolve a single molecule of fibrin. It does not address the underlying mechanism. Sulfonylureas like glipizide force your pancreas to release more insulin from beta cells that are already exhausted from compensating. They lower the A1C by squeezing more output from a failing system. They accelerate beta cell exhaustion. They cause weight gain. They do not address the underlying insulin resistance. They do not clear the fibrin narrowing the microvasculature feeding the pancreas itself. SGLT2 inhibitors like Jardiance cause you to excrete glucose in your urine. They lower the A1C by literally peeing the sugar out. They do not restore insulin signaling. They have specific cardiovascular benefits in certain populations but they do not reverse the disease. GLP-1 agonists like Ozempic suppress appetite and slow gastric emptying. They lower the A1C and produce weight loss. They do not address the receptor-level insulin resistance and the moment they are discontinued the weight and the A1C return. Eventually — for most patients with progressive Type 2 diabetes — insulin therapy. Injections of exogenous insulin to override the failing receptors. The most explicit chemical bypass of the underlying problem. The standard protocol manages blood sugar while the underlying insulin signaling failure, the inflammation it produces, and the fibrin accumulation it drives continue to progress. The protocol does not address the actual mechanism. I have been calling it the endocrinology pharmacy treadmill — and you have been on it for years. You started with the borderline A1C at 49. Your GP said watch it, lose 10 pounds, re-test in six months. You tried. Maybe the scale moved 4 pounds. The A1C kept creeping. At 52 you crossed into diabetic range — 6.5 or 6.8 — and got the metformin prescription. The A1C dropped to 5.9. Your GP congratulated you on the response. Two years later it was 6.3 again despite the medication and you got a higher dose. By 56 you had added glipizide. By 58 your endocrinologist mentioned that you might eventually need insulin if the trajectory continued. By 60 you developed numbness in both feet. By 62 your nephrologist found mild kidney function decline. And the cardiac event, when it comes, is going to be the one that surprises everyone because your A1C has been managed for thirteen years. Every step of this is documented as "successful diabetes management." Every step is moving you further from a body that could have reversed the insulin signaling failure if the inflammation had been addressed and the fibrin cleared at the vascular level. Your endocrinologist is not the one who is going to step you off this treadmill. I want to say that carefully, because I respect endocrinologists. Most of them are good people working inside a broken machine. But I have to be honest about how the machine works. Your endocrinologist has 12 minutes with you. He or she was trained on guidelines that update on a 20-year lag. They were trained to manage glucose with the medication cascade, escalating up to insulin when the oral medications stop working. They were not trained to think of Type 2 diabetes primarily as a receptor-level insulin signaling failure driven by chronic inflammation and compounded by fibrin accumulation in the microvasculature — even though that framing is well-established in the published literature. Dr. Robert Lustig is a Professor Emeritus of Pediatric Endocrinology in the Division of Endocrinology, Diabetes, and Metabolism at the University of California, San Francisco. He has been publishing peer-reviewed metabolic research and advocating for a fundamentally different approach to Type 2 diabetes for over 25 years. He is the author of "Fat Chance" and "Metabolical." He has appeared on national television and in major documentary projects — including the documentary "Fed Up" — specifically to argue that the standard A1C-management protocol over-medicates a condition that often responds to addressing insulin resistance directly through nutritional, metabolic, and anti-inflammatory interventions. Dr. Lustig is still associated with UCSF, one of the most prestigious medical institutions in the country. He is, however, a single physician with a single platform. There are roughly 8,000 endocrinologists practicing in the United States, and most of them are still writing the standard metformin-and-sulfonylurea prescription for the first pre-diabetic patient who walks into their clinic with a borderline A1C. I'm telling you this because there aren't enough Lustigs to go around. You are not going to walk into your local endocrinology clinic and have someone treat your diabetes as an insulin signaling, inflammation, and vascular problem addressable upstream. You are going to get the endocrinologist who has 12 minutes for you and a metformin sample in a drawer. So you are going to have to take the lead. Not by firing your endocrinologist. Not by stopping your medications. Not by doing anything reckless. By learning what the system was never set up to teach you — how to address the actual mechanism the standard protocol is not targeting. The cellular insulin receptors. The chronic inflammation that has driven them into resistance. And the fibrin accumulation that is choking the microvasculature feeding every insulin-sensitive tissue in your body. The compound that dissolves fibrin most directly is an enzyme called nattokinase. It is derived from natto — a traditional Japanese fermented soybean food that people have consumed for thousands of years. Japan has the lowest rate of cardiovascular mortality in the industrialized world. Japanese centenarians — the largest per-capita population of people over 100 on earth — have been consuming natto in whole-food form for generations. The populations that eat natto regularly have among the lowest rates of the exact cardiovascular complications that kill 70% of Type 2 diabetics in the West. This is not a coincidence. It is a mechanism. Nattokinase is a fibrinolytic enzyme. It directly dissolves the fibrin mesh that chronic inflammation has been depositing inside your arterial walls for years. It reduces blood viscosity — literally thinning the blood so it flows more freely through narrowed passages. And it does this systemically, in every artery and every microvessel in the body — including the microvasculature feeding your muscle cells, your pancreatic beta cells, your kidneys, your retinal vessels, your peripheral nerves, and the coronary arteries that will decide how you die. When the microvasculature opens, the tissues it feeds start receiving adequate blood supply again. Muscle cells that have been starved of oxygen and glucose delivery begin responding to insulin more effectively. Beta cells that have been choking on reduced perfusion begin recovering function. The inflammatory loop that has been driving insulin resistance — inflammation → fibrin → narrowed vessels → tissue hypoxia → worsened insulin resistance → more inflammation — begins to break. Multiple published studies have shown nattokinase reduces fibrin deposits, lowers blood viscosity, supports healthy blood pressure, and drops inflammatory markers. A 2024 meta-analysis covering six randomized controlled trials and 546 participants documented measurable improvements in blood pressure and vascular function. The research on fibrin's role in diabetic microvascular complications is published, peer-reviewed, and growing. I want to be careful and honest with you here. This research is not a cure for diabetes. It is not a replacement for the medical evaluation your endocrinologist is providing. The strongest evidence for nattokinase is in cardiovascular and fibrinolytic endpoints, with maturing but not definitive human clinical-trial evidence for diabetes-specific endpoints. Anybody who tells you a softgel "reverses diabetes in 60 days" is lying to you, and you should close their page immediately. But what this research does support is something far more important than another miracle claim. That there is a real, scientifically validated mechanism for dissolving the fibrin accumulation and reducing the inflammation that are compounding the microvascular damage driving Type 2 diabetes progression — a mechanism your endocrinologist was almost certainly never trained on. This is where Vitalyn comes in. I'm not going to insult your intelligence with a "diabetes miracle" pitch. You've seen too many of those. GlucoTrust. Glucofort. Sugar Defender. GlucoBalance. BeLiv. Altai Balance. Sugar Mac. The "African ritual" angle. The "5-second sugar trick" angle. The "blood sugar parasite" angle. You've been burned. So have your friends. I'm going to do the opposite. Vitalyn is built around 4,000 fibrinolytic units of nattokinase per softgel — the full clinical dose from the published cardiovascular research — in a single enteric-coated softgel suspended in MCT oil. Most nattokinase on the market does not work. Nattokinase is a fragile enzyme. When you swallow a standard dry-powder capsule, your stomach acid destroys approximately 85 percent of the enzyme before it ever reaches your bloodstream. You are swallowing nattokinase. Almost none of it is reaching your arterial walls. Vitalyn solves this with a dual delivery system. The enteric coating protects the enzyme through the stomach and releases it in the small intestine where it can actually be absorbed. The MCT oil enhances absorption so the enzyme reaches the arterial walls where the fibrin lives. No other nattokinase brand on the market combines both. But nattokinase alone is only one piece. The diabetic physiology has multiple inflammatory and metabolic input pathways. So Vitalyn stacks six companion ingredients, each chosen because there is published research on its role in inflammation, vascular health, or metabolic-relevant biomarkers. Turmeric — one of the most published anti-inflammatory compounds in the nutritional literature. Directly suppresses the NF-κB inflammatory cascade that drives both insulin resistance progression and fibrin deposition on arterial walls. It addresses the upstream trigger — stopping the inflammation that causes fibrin to accumulate in the first place, so the nattokinase can clear what is already there. Bromelain — provides secondary fibrin breakdown through a distinct enzymatic pathway. Published research on systemic inflammation reduction. Works alongside nattokinase to accelerate fibrin clearance throughout the microvasculature. Ginger — supports circulation and blood flow through vasodilation. Published research on inflammatory marker reduction. Supports glucose metabolism. CoQ10 — cellular energy for the heart muscle and for beta cells. CoQ10 depletion is documented in diabetic populations and in statin users — and most Type 2 diabetics over 50 are on a statin. Repletes the cellular energy the heart and the pancreas need to function under metabolic stress. Olive leaf — antioxidant and vascular protector. Published research on endothelial function support through a pathway distinct from fibrin dissolution. Supports the vessel wall integrity that chronic inflammation has been degrading. White willow bark — nature's original aspirin. Natural anti-platelet support without the gastric destruction. Particularly relevant for diabetic patients whose chronic inflammation is already driving platelet aggregation risk — the same mechanism that produces the cardiac event the coroner writes on the death certificate. That is the formula. Seven ingredients. Each one published. One softgel a day. I want to draw a hard line. Vitalyn is not a cure for diabetes or insulin resistance. It is not a "reverse your diabetes in 60 days" miracle. It is an upstream intervention supporting microvascular clearing and the inflammatory environment that drives Type 2 diabetes progression. It is not a replacement for the medications your endocrinologist has prescribed. Do not stop metformin, sulfonylureas, SGLT2 inhibitors, GLP-1 agonists, or insulin without your endocrinologist's involvement. When you start to see your A1C improve — and many people do — bring that data to your endocrinologist and ask about adjusting the protocol. It is not instant. Insulin resistance has been progressing in your body for years. The fibrin has been accumulating for decades. The fastest-acting ingredients begin dissolving fibrin and reducing inflammation within days. The deeper work of restoring microvascular flow to insulin-sensitive tissues happens over weeks and months. That is why our guarantee is 90 days. That is the line. Now let me tell you what the people using Vitalyn have started to notice. Results not typical, individual results may vary, statements not evaluated by the FDA, not intended to diagnose, treat, cure, or prevent any disease. The first thing most people notice is afternoon energy. Specifically, the post-meal crash that diabetic and pre-diabetic patients experience after lunch begins to disappear. This is the most consistent feedback we get in the first two to three weeks. The reason is direct — when microvascular flow to muscle tissue improves and cellular insulin signaling begins to recover, postprandial glucose handling normalizes, and the afternoon energy crash that comes from inefficient glucose disposal lifts. The second thing is sleep quality. Sleep architecture in diabetic and pre-diabetic patients is often disrupted by nighttime glucose dysregulation. Many users report sleeping more deeply and waking less frequently within three to four weeks. The third thing is stamina. The cascading effects of improved microvascular flow and reduced blood viscosity show up as improved exercise tolerance, faster recovery from physical activity, and the ability to do things you had stopped doing because your energy didn't support them. Many users report this within six to eight weeks. The fourth thing is the bedroom — and this is critical. Erectile dysfunction is one of the most under-discussed complications of Type 2 diabetes. The same microvascular dysfunction driving the disease silently impairs erectile function. The penile arteries are the smallest in the male body — they clog with fibrin first, years before the coronary arteries. Unlike metformin, which does nothing for erectile function, and unlike SGLT2 inhibitors which can sometimes cause genital infections, nattokinase dissolves the fibrin narrowing the penile arteries while simultaneously clearing the microvasculature feeding every other insulin-sensitive tissue. Many men on Vitalyn report sexual function improving while their metabolic markers also improve. The fifth thing — and this is the one that takes 2 to 4 months — is the A1C and the HOMA-IR. Many users come back from their next endocrinology appointment with an A1C 0.5 to 1.0 points lower than the previous reading, and a fasting insulin and HOMA-IR moving from significant insulin resistance toward normal range. Their endocrinologist looks at the chart and asks what they've changed. They tell their endocrinologist. Some are intrigued. Some are skeptical. Almost all of them say, keep doing whatever you're doing. The deepest piece of feedback we ever got was from a man in Tennessee who wrote to us seven months in: "My dad died of a heart attack at 64. He had been on metformin for 18 years and his A1C had been 'controlled' the whole time. I was on the same trajectory at 58. My A1C this month is 5.4 — the first time it has been under 5.7 in twelve years. My doctor took me off the glipizide. I think I might not have to be my dad." That letter is on the wall. I know you're skeptical. The diabetes-supplement industry has earned every ounce of your distrust. So let me be plain. The mechanism is real. Fibrin accumulation in the microvasculature is a documented driver of diabetic complications. Nattokinase's fibrinolytic activity is published, peer-reviewed, and replicated. The role of chronic inflammation in insulin resistance is established at every major endocrinology academic department in the country. Type 2 diabetes as a cellular insulin signaling problem compounded by microvascular fibrin accumulation is published, validated, and on record through Lustig at UCSF and through the broader vascular research literature. The label is transparent. Every milligram listed. No proprietary blends. The guarantee is 90 days. Get a baseline A1C, fasting glucose, fasting insulin, and HOMA-IR. Take Vitalyn for the full period. Retake the labs. If your numbers haven't moved meaningfully, return whatever's left — full or empty — full refund. No interrogation. I want you to picture two different futures. In one future, you keep doing what you're doing. The metformin keeps managing the A1C. Your endocrinologist adds glipizide at the next escalation. Within two years your beta cells exhaust further and the A1C climbs back despite combination therapy. Add an SGLT2 inhibitor. Then a GLP-1 agonist. Then eventually basal insulin. Then mealtime insulin. Then the first complication you weren't expecting — the peripheral neuropathy that started in your toes, the diabetic retinopathy your ophthalmologist found at your annual eye exam, the slight elevation in your creatinine that becomes stage 3 kidney disease over the next decade. Then maybe — somewhere between 62 and 72 — a coroner writes "acute myocardial infarction" on the certificate. The actual disease that killed you — the insulin signaling failure nobody treated, the inflammation that was never measured, the fibrin that accumulated in every artery for fifteen years while your A1C looked controlled — will not appear on it. In the other future, you start a program today that targets the actual vascular and inflammatory mechanism compounding your disease. You give it 90 days. You watch your afternoon energy return. You watch your sleep deepen. You watch your A1C come back lower than it has been in years. You watch your fasting insulin and HOMA-IR move from significant insulin resistance toward normal. You go to the endocrinologist and have the conversation about deferring or reducing the medications they were going to escalate. You preserve your kidney function. You preserve your peripheral nerves. You preserve your retinal health. You preserve your erectile function. You break the family pattern. That is not a guarantee. I am not allowed to make that guarantee. But it is what is possible. And it is what is not possible if the next medication gets added at your next appointment. If you've read this far, you already know. You knew before you started reading. You knew when your A1C crossed 6.0. You knew when your endocrinologist mentioned "we might need to add something." You knew when you watched your father or your uncle or your older brother go through the cascade that ended with the cardiac event nobody saw coming. You don't need another piece of evidence. You need 90 days before the next medication gets added. This is both. Tap below to order Vitalyn, backed by our 90-day money-back guarantee. One softgel a day. One mechanism your endocrinologist was never trained on. One chance — at 50, 55, 60 — to be the person who addressed the vascular and inflammatory root upstream of the medication cascade instead of the person whose cardiac event surprised everyone because their A1C had been managed for the previous fifteen years. I'll see you on the other side of 90 days. thevitalynlab.com/products/nattokinase-4000-fu-daily-complex

Where the ad sends people

thevitalynlab.com

The Coroner Doesn't Write 'Diabetes' On The Death Certificate.

Support strong circulation today with our powerful nattokinase formula.